Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEOPATTRA: NNC6019-0001 vs placebo in transthyretin amyloid cardiomyopathy
ChiCTR2600121167Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing NNC6019-0001 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Number of occurrences of the composite cardiovascular endpoint. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on ChiCTR2600121167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121167.